{
    "2021-11-05": [
        [
            {
                "time": "2023-10-18",
                "original_text": "Top Analyst Reports for Tesla, Comcast & AbbVie",
                "features": {
                    "keywords": [
                        "analyst reports",
                        "Tesla",
                        "Comcast",
                        "AbbVie"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "technology",
                        "media",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-18",
                "original_text": "Ironwood (IRWD) Q3 Earnings Top, Sales Hurt by Lower Price",
                "features": {
                    "keywords": [
                        "Ironwood",
                        "Q3 earnings",
                        "sales",
                        "lower price"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-10-18",
                "original_text": "AbbVie Presents Integrated Efficacy and Safety Data From Two Phase 3 Trials on Risankizumab (SKYRIZI®) in Psoriatic Arthritis at ACR Convergence 2021",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "efficacy",
                        "safety data",
                        "Phase 3 trials",
                        "Risankizumab",
                        "SKYRIZI®",
                        "Psoriatic Arthritis"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-18",
                "original_text": "Testing May Take Awhile, but Gene Therapy Is Poised to Tackle Mass Diseases",
                "features": {
                    "keywords": [
                        "gene therapy",
                        "mass diseases",
                        "testing"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}